piMed Consulting

What piMed Consulting does

piMed Consulting (piMedConsulting AG) is a Swiss translational medicine consultancy founded in 2018 and headquartered in Gersau, Switzerland. The firm advises biotech companies and diagnostic startups on reducing risk across pharmaceutical drug development, with a core focus on biomarker identification and the design of rational, investment-conscious clinical development plans. Its services are organized around three stages — translating science into molecules, converting molecules into medicines, and transforming medicines into therapies — and explicitly target early-stage life sciences companies seeking to reach milestones such as asset sales to global pharma or ROI-positive exits.

The company is led by two principals. Eva Pisa (Co-owner, CEO) holds a PhD in Immunology from the Karolinska Institute and an MBA from Heriot-Watt University; her prior roles include R&D and business positions at Roche Diagnostics International and she previously transitioned a diagnostic startup to acquisition by Cepheid (now part of Danaher). Pavel Pisa (Founder) is an M.D./Ph.D. with 120 peer-reviewed highly cited publications in tumor immunology and cancer immunotherapy, prior academic and clinical leadership at the Karolinska Institute, and key contributor roles on cancer immunotherapy programs at Roche Pharmaceuticals; he received the British Pharmacological Society's Drug Discovery of the Year Award in 2015. Jointly the team has over 60 years of experience in drug development and diagnostics.

Revenue is generated through project-based professional consulting engagements delivered directly by the founders. The go-to-market is sales-led, relying on professional networks and industry connections rather than digital marketing or channel partnerships, with a basic company website as the primary digital presence. No external funding rounds, acquisitions, partnerships, patents, or formal certifications have been disclosed. The firm operates with 1-10 employees and has supported multiple startup companies to reach milestones including asset sales to global pharma companies.

Name

piMed Consulting

Legal name

piMedConsulting AG

Website

https://pimedconsulting.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

piMed Consulting is a Swiss translational medicine consultancy founded in 2018 that advises biotech and diagnostic startups on biomarker identification and clinical development planning to reduce risk across pharmaceutical drug development, led by founders with prior Roche and Karolinska experience.

Ownership category

akta.pro rank

Product category

Pharmaceutical Consulting Services

NAICS

Other Scientific and Technical Consulting Services (54169), Management Consulting Services (54161)

SIC

Services-Management Consulting Services (8742), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Translational Medicine & Biomarkers (HLAIALAF)

akta.pro secondary industry

Innovation, Product & R&D Consulting (BPAHACAM)

Keywords

• Translational medicine consulting
• Clinical development planning
• Biomarker identification services
• Drug development advisory
• Biotech consulting services

Headquarters

HQ city

Gersau

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Consulting Services: Professional advisory services in translational medicine and biomarker development, likely structured as project-based consulting engagements or retainer arrangements with biotech companies and diagnostic startups.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

piMed Consulting provides expert translational medicine advisory services to biotech and diagnostic companies, spanning the entire pharmaceutical development journey from translating science into molecules, converting molecules into medicines, and transforming medicines into therapies. The firm delivers biomarker identification, clinical development planning, and technology and commercial expertise, focusing on reducing risks and minimizing pitfalls in early drug development through rational, investment-conscious clinical development plans.

Product overview

piMed Consulting offers a unified translational medicine consultancy service rather than a software product or platform. Their core offering comprises expert advisory services spanning three key development phases: translating science into molecules, converting molecules into medicine, and transforming medicine into therapy. The firm provides biomarker identification, clinical development planning, and technology and commercial expertise to biotech and diagnostic startup companies. The service is delivered by two principal experts—Eva Pisa (CEO, co-owner) and Pavel Pisa (founder)—who collectively bring over 60 years of experience in drug development and diagnostics across pharmaceutical companies including Roche and academic institutions such as the Karolinska Institute.

Differentiator

Problem solved

Functional benefit

Products and services

• Translational Medicine Consultancy Services Expert advisory services supporting drug development from early scientific research through clinical development to patient therapy, focused on biomarker identification, clinical development planning, and technology and commercial expertise. Designed for biotech and diagnostic startup companies seeking to reduce risks and minimize pitfalls when developing pharmaceutical assets. Delivered by Eva Pisa (CEO, Co-owner) and Pavel Pisa (Founder) with over 60 years of combined experience in drug development and diagnostics.

Quantifiable outcome

• Multiple startup companies supported to reach important business milestones including asset sales to global pharma companies and achieving ROI

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves3 records

Expansion highlights1 record

Broad incumbents

• ICON plc: ICON is a global CRO offering clinical development, biomarker, and translational medicine services to pharma and biotech. It competes with piMed for biotech translational/biomarker advisory budgets but at much greater scale and with broader service bundling.
• IQVIA: IQVIA is a global CRO and healthcare analytics firm offering translational medicine, biomarker strategy, and clinical development consulting as part of a much broader portfolio. It is comparable to piMed because biotech clients can engage it for similar translational/biomarker advisory, though IQVIA competes at a vastly larger scale and integrated-services level.
• Covance (Labcorp Drug Development): Labcorp Drug Development (formerly Covance) provides early development, biomarker, and translational services to biotech. Comparable to piMed in serving the same translational/biomarker use case, but as part of a global diagnostics and CRO platform.
• Parexel International: Parexel is a global CRO that provides clinical development planning and translational/early-phase advisory to biotech and pharma clients. It overlaps with piMed on clinical development strategy and biomarker-driven trial design, but operates as a full-service CRO with thousands of employees.
• Charles River Laboratories: Charles River is a global CRO/CDMO with consulting and discovery services supporting early-stage biotechs. It is comparable to piMed as a partner for biotechs needing advisory on translational and biomarker strategy, though its primary differentiator is laboratory services rather than senior-led consulting.

Direct peers

• Health Advances: Health Advances is a healthcare strategy consultancy advising biotech, diagnostics, and medtech companies on clinical and commercial strategy. It is a strong direct peer given its diagnostics focus (overlapping with Eva Pisa's background) and senior-led biotech advisory model similar to piMed.
• Triangle Insights Group: Triangle Insights Group is a strategy and consulting firm advising biotech and pharma on clinical development, asset strategy, and commercial planning. It overlaps directly with piMed's development planning and biotech advisory use cases, with a similar boutique senior-consultant delivery model.
• Defined Health: Defined Health is a boutique strategic consultancy advising biotech and pharma on clinical development strategy, asset positioning, and partnering. It is a direct peer to piMed given its senior-expert model serving similar biotech clients on translational and development planning decisions.
• Lachman Consultant Services: Lachman Consultants is a pharmaceutical consulting firm specializing in drug development, regulatory, and technical advisory for pharma and biotech. It overlaps with piMed's development planning and biotech advisory scope, though with a stronger regulatory/GMP lean.
• Alacrita Consulting: Alacrita is a life sciences consulting firm providing drug development, clinical strategy, and translational advice to biotech and pharma clients. It is directly comparable to piMed as a boutique pharma/biotech consultancy with similar translational medicine and development planning offerings.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/pimed-consulting-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about piMed Consulting